NOMINATIONS ARE OPEN FOR THE 2021 DR. PAUL JANSSEN AWARD!

January 14, 2021
Janssen Pharmaceutical Companies

Nominations Open Please submit nominations by February 28, 2021. Thank you for taking the time to make a nomination for the Dr. Paul Janssen Award. Please remember to consult the criteria for the nomination. Please note that the entire nomination form needs to be completed in one sitting. Please ensure you have all the information you need to complete … Continue reading NOMINATIONS ARE OPEN FOR THE 2021 DR. PAUL JANSSEN AWARD!

BIOTECanada is pleased to announce the launch of Bio+ech Connec+

January 13, 2021
BIOTECanada

January 13, 2021 – BIOTECanada is pleased to announce the launch of Bio+ech Connec+, a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies. The first Bio+ech Connec+ will take place on February 9 featuring Gilead Sciences Canada Inc. This virtual forum will include a plenary session led … Continue reading BIOTECanada is pleased to announce the launch of Bio+ech Connec+

New IMC Report Shows Impact of Chronic Disease and Increased Claims on Private Drug Plans

January 13, 2021
Innovative Medicines Canada (IMC)

Ottawa, January 13, 2021 – Growth in chronic disease and increased drug claims are two of the key factors driving up the cost of private health benefit plans, according to Innovative Medicines Canada’s 2016-2019 Analysis of Private Drug Claim Cost Drivers report, released today. The report also finds that drug claim costs are rising at … Continue reading New IMC Report Shows Impact of Chronic Disease and Increased Claims on Private Drug Plans

Kintara Announces Initiation of Patient Recruitment for VAL-083’s Study Arm in the GBM AGILE Trial

January 13, 2021
Kintara Therapeutics, Inc.

SAN DIEGO, Jan. 13, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that patient recruitment has commenced in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma (GBM).  The trial, titled GBM AGILE (Glioblastoma … Continue reading Kintara Announces Initiation of Patient Recruitment for VAL-083’s Study Arm in the GBM AGILE Trial

Silicon Valley Bank – Healthcare Investments & Exits 2021 Annual Report

January 12, 2021
Silicon Valley Bank

January 12, 2021 – At a time when innovation is more important than ever, our proprietary life sciences and healthcare research reveals that 2020 proved to be a banner year for healthcare venture fundraising and investment – the future looks bright for life science companies and investors.    To view and download the full report:   Click here to download the report

AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO

January 8, 2021
AbCellera Biologics Inc.

January 8, 2021 – After Carl Hansen co-founded AbCellera Biologics Ltd. in 2012, people constantly told him he was building a biotechnology company the wrong way. “The whole sector for years has been focused on this idea that if you wanted to build a valuable company, you have to make your own drugs,” Dr. Hansen … Continue reading AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

January 8, 2021
InMed Pharmaceuticals Inc.

Vancouver, BC – January 8, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced top-line results from its 755-102-HV Phase 1 clinical trial (“Study 102”). Results of … Continue reading InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

January 8, 2021
Neoleukin Therapeutics Inc.

SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 … Continue reading Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences

January 8, 2021
Aurinia Pharmaceuticals Inc.

January 8, 2021 – VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and participate in a panel discussion hosted by Dr. Scott Gottlieb, former FDA Commissioner: H.C. Wainwright Virtual BioConnect 2021 Conference. On-demand … Continue reading Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences

Symvivo Announcing Research Collaboration with Merck

January 7, 2021
Symvivo Corporation

January 5, 2021 – Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s … Continue reading Symvivo Announcing Research Collaboration with Merck